Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead To Close R&D Labs In Durham, N.C.

by Ann M. Thayer
July 5, 2010 | A version of this story appeared in Volume 88, Issue 27

To consolidate its antiviral R&D efforts at its Foster City, Calif., headquarters, Gilead Sciences will close its Durham, N.C., research site by the end of 2010. The move will affect 150 jobs; about 20% of the employees have been offered relocation packages. The company acquired the site when it purchased Triangle Pharmaceuticals in 2003. The acquisition led to the development of the HIV/AIDS drug Emtriva, which is sold combined with another Gilead drug, Viread. Sales of the combination, called Truvada, were $658 million in the first quarter.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.